FRIDAY, Sept. 22, 2023 (HealthDay News) – New research suggests some newer diabetes treatments may not be as beneficial for Black patients, after earlier drug trials included small numbers of non-white people. Whether the medications — called sodium-glucose co-transporter 2 inhibitors (SGLT2-Is) and glucogen-like peptide 1 receptor agonists (GLP1-Ras) —Continue Reading

THURSDAY, Sept. 21, 2023 (HealthDay News) — Helping undocumented immigrants in the United States connect with primary care doctors could be a money-saver, substantially reducing emergency department use and lowering health costs, a new study finds. The findings are from a New York City program that helped arrange medical appointmentsContinue Reading

WEDNESDAY, Sept. 20, 2023 (HealthDay News) — In a surprising move, the U.S. Food and Drug Administration (FDA) has opted not to approve a needle-free alternative to the EpiPen for emergency treatment of severe allergic reactions. Approval of the Neffy nasal spray was widely anticipated. An FDA advisory panel votedContinue Reading

WEDNESDAY, Sept. 20, 2023 (HealthDay News) — Another diabetes drug maker is taking legal action against businesses in several states, alleging that they’re “fraudulently claiming” that their compounded products are the same as its medication. This time, it’s Eli Lilly suing certain medical spas, wellness centers and compounding pharmacies overContinue Reading

MONDAY, Sept. 18, 2023 (HealthDay News) — Perhaps succumbing to fraudsters or facing mounting bills, older Americans begin losing wealth in the years preceding a definitive dementia diagnosis, new research shows. For example, the median household net worth of the seniors in the study dropped by more than half inContinue Reading